Indoco Remedies Posts ₹40.4 Crore Net Loss in Q4 FY25

26 May 2025 , 08:14 PM

Indoco Remedies Ltd. posted a consolidated net loss of ₹40.4 crore for the quarter ended March 31, 2025, a sharp contrast from a net profit of ₹22.7 crore in the same period a year ago. The deterioration in the company’s performance was driven by a 12.5% year-on-year fall in total revenues at ₹384 crore in Q4 FY25 from ₹439 crore in Q4 FY24. The decline in revenues was a primary contributor to the change in profit to loss, amid challenges in both domestic and overseas markets.

Aditi Panandikar, Managing Director of Indoco Remedies said, “While it was a difficult year for the company, the primary focus would be the future growth prospects”. Referring to the various positive triggers in the pipeline which she said would drive both short term and long term recovery, Panandikar said, “We are confident of achieving long term growth”.

Though results for the quarter were weak, the board of directors has proposed a final dividend of ₹0.20 per equity share of face value of ₹2 each for the financial year, which is subject to approval of members at the ensuing AGM.

Indoco Remedies LTD still upholding its strong position in pharmaceutical industry engaged in the business of production, marketing and development of finished dosage formulations and APIs. The company has a strong foothold in the Indian pharma market as well as in the international market where it sells its products in more than 55 countries and is also expanding its product portfolio.

Established in 1947 after Independence, Indoco Remedies is a leading pharmaceutical company in India promoting new developments in the area of contract research and manufacturing to support wider innovations across the healthcare spectrum.